The three-year loss for 1&1 (ETR:1U1) shareholders likely driven by its shrinking earnings
While the stock has risen 7.3% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.
View our latest analysis for 1&1
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
1&1 saw its EPS decline at a compound rate of 3.0% per year, over the last three years. This reduction in EPS is slower than the 16% annual reduction in the share price. So it's likely that the EPS decline has disappointed the market, leaving investors hesitant to buy. This increased caution is also evident in the rather low P/E ratio, which is sitting at 8.67.
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
This free interactive report on 1&1's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
1&1 shareholders are down 25% for the year (even including dividends), but the market itself is up 18%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 6% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand 1&1 better, we need to consider many other factors. For instance, we've identified 1 warning sign for 1&1 that you should be aware of.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
N26 co-founder Valentin Stalf to step down
This story was originally published on Banking Dive. To receive daily news and insights, subscribe to our free daily Banking Dive newsletter. N26 co-founder Valentin Stalf will step down as co-CEO and move to a role on the German digital bank's supervisory board after a transition period, the company announced Tuesday. That leaves Stalf's fellow co-founder, Max Tayenthal, as N26's sole CEO for the moment, though the digital bank's chair, Marcus Mosen, may be appointed interim co-CEO soon, the Financial Times reported last week. The executive shuffle comes as German financial watchdog BaFin last month proposed issuing a formal warning to two members of the bank's management board and appointing a special monitor after finding new risk management weaknesses, according to the Financial Times. The potential development arises little more than a year after BaFin lifted a cap it had put on N26's growth. The nearly three-year cap cost the digital bank billions in lost valuation, including a shutdown of its U.S. operations in 2021. Stalf's shift comes amid reports that he and Tayenthal may waive special voting rights that give them veto power over certain decisions. Stalf and Tayenthal together hold a roughly 20% stake in the company. U.K.-based fintech Wise, similarly, last month held its own referendum on investors who hold so-called 'golden share' supervoting powers. Stalf, in a statement Tuesday, called his move 'a forward-looking decision to continue to best utilize my many years of experience and knowledge to strengthen N26.' 'I will actively and passionately contribute to N26's long-term leadership and strategic direction and will remain one of the largest N26 shareholders,' he said. 'The new role also offers me the opportunity to devote more time to my family office and other entrepreneurial pursuits.' Stalf told the Financial Times he had been thinking about leaving the company's management 'for some time' and expedited the transition after rumors of his potential departure last week. He added he expects to join the supervisory board after roughly six months. Stalf further said he expected two more executives to join the management board 'over the coming six to 12 months' but declined to detail potential future management changes. A person familiar with discussions at N26 told the Financial Times that Tayenthal was likely to step down from his role at a later stage. The digital bank, however, said Tayenthal 'remains fully committed to his role.' Mosen, for his part, called Stalf 'a pioneer in mobile banking.' 'I have tremendous respect for his entrepreneurial vision and achievements,' Mosen said in a Tuesday release. 'Together with Max, he has turned N26 into an industry frontrunner and market-leading digital bank known across Europe. I look forward to continuing our cooperation." N26 broke even last summer, it said, adding it delivered 40% revenue growth in its past financial year and annual revenues now exceeding €500 million. The digital bank is preparing to introduce products for families, including a child's account, card and investment functionality; a new premium subscription with exclusive partners; and an all-new app design focused on holistic wealth management, it said. On the risk management front, the company's pending chief risk officer, Jochen Klöpper, is set to start in December. Recommended Reading Goldman's global banking and markets co-chief to leave bank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Noodles, GoodRx, Micron, Custom Truck One Source, and CarMax Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this trend is that much of the recent market gains were concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed. Despite the downturn, some analysts viewed this as an opportunity to own some of the "Core AI winners." Dan Ives of Wedbush Securities commented, "In our view, the tech bull cycle will be well intact for at least another 2-3 years, given the trillions being spent on AI infrastructure/software/chips/power/apps looking ahead. This remains our tech playbook and investor roadmap." Additionally, mixed earnings reports from retailers, such as Target, have added to the market's weakness. Investors are closely monitoring these reports for insights into the broader economic health and the potential impact of new tariffs on inflation. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Modern Fast Food company Noodles (NASDAQ:NDLS) fell 5.8%. Is now the time to buy Noodles? Access our full analysis report here, it's free. Healthcare Technology for Patients company GoodRx (NASDAQ:GDRX) fell 7.7%. Is now the time to buy GoodRx? Access our full analysis report here, it's free. Memory Semiconductors company Micron (NASDAQ:MU) fell 5.8%. Is now the time to buy Micron? Access our full analysis report here, it's free. Specialty Equipment Distributors company Custom Truck One Source (NYSE:CTOS) fell 4.9%. Is now the time to buy Custom Truck One Source? Access our full analysis report here, it's free. Vehicle Retailer company CarMax (NYSE:KMX) fell 4.3%. Is now the time to buy CarMax? Access our full analysis report here, it's free. Zooming In On GoodRx (GDRX) GoodRx's shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 40.2% on the news that the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers. This landmark collaboration makes the popular GLP-1 medications—used for type 2 diabetes (Ozempic) and weight loss (Wegovy)—available at a significantly lower cost to those who lack adequate insurance coverage. According to the announcement, this marks the first time Ozempic has been offered at this self-pay price point. The offer is effective immediately and available through the GoodRx platform at over 70,000 retail pharmacies nationwide. Investors reacted positively, viewing the strategic partnership as a pivotal move that could substantially expand GoodRx's market reach and user base by capitalizing on the high-demand therapeutic category. GoodRx is down 3.6% since the beginning of the year, and at $4.40 per share, it is trading 48.8% below its 52-week high of $8.59 from August 2024. Investors who bought $1,000 worth of GoodRx's shares at the IPO in September 2020 would now be looking at an investment worth $87.03. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
3 hours ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
